XML 64 R46.htm IDEA: XBRL DOCUMENT v3.26.1
SHARE-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2025
SHARE-BASED COMPENSATION [Abstract]  
Employee Share Option Activity
The following table summarizes the Company’s share option activity under the Plan:

 
Number of
options
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
term
   
Aggregate
intrinsic value
 
          $    
Years
    $  
                             
Outstanding, January 1, 2023
   
68,533,186
     
60.87
               
Granted
   
1,925,000
     
60.00
               
Cancelled or forfeited
    (9,292,295 )     104.02                
Exercised
   
(1,336,980
)
   
7.19
               
Outstanding, December 31, 2023
   
59,828,911
     
55.34
     
6.18
     
944,611
 
Vested and exercisable as of December 31, 2023
   
42,877,386
     
35.29
     
5.51
     
887,174
 
Outstanding, January 1, 2024
   
59,828,911
   

                 
Cancelled
   
(6,600,000
)
   
120.00
                 
Exercised
   
(10,148,635
)
   
14.40
                 
Outstanding, December 31, 2024
   
43,080,276
     
55.08
     
5.24
     
2,426,627
 
Vested and exercisable as of December 31, 2024
   
36,830,100
     
47.63
     
5.00
     
2,312,733
 
Outstanding, January 1, 2025
   
43,080,276
                         
Exercised
   
(3,823,890
)
    14.87                  
Outstanding, December 31, 2025
   
39,256,386
     
59.00
     
4.44
     
2,691,965
 
Vested and exercisable as of December 31, 2025
   
36,006,386
     
54.22
     
4.29
     
2,641,113
 
Assumptions Used for Estimated Fair Value of Options
The Company calculated the estimated fair value of the options on the respective grant dates using the Black-Scholes Option Pricing Model with the following assumptions:

 
Granted in 2023
 
       
Risk-free interest rates
   
3.60% – 4.10%

Expected term
 
6.5 – 7 years
 
Expected volatility
   
60.2% – 62.0%

Expected dividend yield
   
 
RSAs/RSUs Activity
The following table summarizes the Company’s RSAs/RSUs activity under the Plan:

 
Number of
RSAs/RSUs
   
Weighted
average grant
date fair value
   
Weighted
average
remaining
contractual life
   
Aggregate
intrinsic value
 
         
$
   
Years
   
$
 
                         
Unvested, January 1, 2023
   
9,652,231
     
120.48
     
8.81
     
502,206
 
Granted
   
7,119,505
     
63.46
                 
Vested
   
(4,130,583
)
   
109.11
                 
Forfeited
   
(1,786,921
)
   
116.01
                 
Unvested, December 31, 2023 and January 1, 2024
   
10,854,232
     
90.02
     
8.86
     
439,596
 
Granted
   
10,718,971
     
48.32
                 
Vested
   
(6,099,527
)
   
93.83
                 
Forfeited
   
(1,688,983
)
   
73.93
                 
Unvested, December 31, 2024 and January 1, 2025
   
13,784,693
     
82.18
     
8.74
     
1,462,556
 
Granted
   
1,268,009
     
132.41
                 
Vested
   
(5,494,734
)
   
93.05
                 
Forfeited
   
(947,634
)
   
66.27
                 
Unvested, December 31, 2025
   
8,610,334
     
84.39
     
8.06
     
1,098,420
 
Total Compensation Expense of Share Options, RSAs, RSUs and SARs Granted to Employees
Total compensation expense relating to share options, RSAs, RSUs and SARs granted to employees after deducting forfeitures recognized for the years ended December 31, 2023, 2024 and 2025 is as follows:

 
Year ended December 31,
 
   
2023
   
2024
   
2025
 
             
                         
Share options:
                       
General and administrative expenses
   
253,408
     
155,051
     
115,087
 
Research and development expenses
   
44
     
     
 
     
253,452
     
155,051
     
115,087
 
                         
Cash received for the exercise in the respective years
   
10,643
     
146,081
     
56,825
 
                         
RSAs/ RSUs:
                       
Cost of revenue
   
12,727
     
10,795
     
9,071
 
Sales and marketing expenses
   
35,988
     
32,257
     
25,279
 
General and administrative expenses
   
99,048
     
231,610
     
258,466
 
Research and development expenses
   
282,381
     
274,624
     
208,530
 
     
430,144
     
549,286
     
501,346
 
                         
SARs:
                       
Cost of revenue
   
383
     
2,235
   
1,306
 
Sales and marketing expenses
   
710
     
4,125
   
3,578
 
General and administrative expenses
   
200
     
4,197
   
3,238
 
Research and development expenses
   
141
     
945
   
440
 
     
1,434
     
11,502
   
8,562